Welcome to our dedicated page for JMDP news (Ticker: JMDP), a resource for investors and traders seeking the latest updates and insights on JMDP stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect JMDP's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of JMDP's position in the market.
Stella Diagnostics, Inc. (OTC PINK:JMDP) has officially changed its corporate name from JMP Properties, Inc. to Stella Diagnostics, Inc., effective April 16, 2021. Alongside the name change, the company’s common stock will now trade under the new ticker symbol SLDX. This rebranding aligns with the company's mission to enhance patient management strategies for over 67 million individuals suffering from severe esophageal diseases. CEO Dr. Joe Abdo emphasizes that the name and ticker change are crucial for strengthening their brand and mission.
Stella Diagnostics (OTC Markets: JMDP) will participate in the Benzinga Biotech Small Cap Conference from March 24-25, 2021. CEO Dr. Joe Abdo is scheduled to present a corporate update and engage in a live Q&A session starting at 2:10 PM EDT on March 24. The conference aims to connect investors and executives from small-cap biotech firms. Stella Diagnostics focuses on improving treatment strategies for over 67 million patients with severe esophageal diseases through innovative molecular diagnostics. More information can be found at www.stelladx.com.
Stella Diagnostics, Inc. (OTC PINK:JMDP) has entered a Collaborative Research Agreement with the University of Kansas Medical Center to evaluate the effectiveness of its STLA101 panel in patients with Barrett's esophagus. The research, led by Dr. Ajay Bansal, aims to analyze proto-oncogenes in tissue samples to understand the mechanisms behind disease progression to esophageal adenocarcinoma. This partnership seeks to enhance risk stratification and improve patient management, critical for the estimated 6 million Americans affected by Barrett's esophagus.
Stella Diagnostics, Inc. (OTC PINK:JMDP) has appointed Peter A. Cohen, Seth Platt, and David Seaburg to its Board of Directors, enhancing its leadership with seasoned experts in asset management and corporate development. Dr. Joe Abdo emphasized the importance of these appointments for the company's growth in the biotech sector. Cohen brings over 50 years of experience in investment banking, while Platt and Seaburg add significant operational and market experience. This strategic move aims to position Stella as a leader in molecular oncology, focusing on severe esophageal diseases.
Stella Diagnostics, Inc. (OTC PINK:JMDP) announced a Collaborative Research Agreement with the Mayo Clinic to evaluate the clinical utility of its STLA101 panel in predicting disease progression in patients with Barrett's esophagus. The study will analyze expression patterns of proto-oncogenes and biomarkers in over 100 patients over a 10-year period. With esophageal adenocarcinoma's incidence rising by 700% in the U.S., this collaboration is aimed at enhancing screening techniques to aid gastroenterologists in patient management.
Stella Diagnostics (OTC PINK:JMDP) has partnered with mProbe, Inc. to enhance its proteomic biomarker panel for detecting precancerous esophageal tissues. This collaboration aims to validate the STLA101 panel designed to predict the risk of Barrett's esophagus progressing to esophageal cancer. Clinical samples will be analyzed to assess the panel's effectiveness, with results expected to be shared at major medical conferences. This initiative aims to improve patient management for the 67 million Americans suffering from severe esophageal conditions.
Stella Diagnostics, Inc (OTC PINK:JMDP) announced that CEO Dr. Joe Abdo will present at the 32nd EORTC NCI AACR Symposium on October 24-25, 2020. The presentation focuses on research regarding esophageal adenocarcinoma, the fastest rising cancer in the U.S., with a 600% increase in incidence over 25 years. Dr. Abdo's study identifies biomarkers linked to resistance against common chemotherapies, highlighting a need for new diagnostic and treatment options for patients. The presentation will be available on demand through the conference website.
